Ishmael Jaiyesimi, DO
Hematology & Oncology · Royal Oak, MINPI 1538128178
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.7%), other and consulting fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Novartis at 32.9% of the total.
Across 206 payments — averaging $41.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Johnson & Johnson$2K
- Gilead$410
- Merck$237
- Amgen$237
- Pfizer$206
- plus $3K from 33 others
Across 6 payments — averaging $85,113 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$390K
- Merck$101K
- AstraZeneca$16K
- QED Therapeutics, Inc.$4K
What the payments were for
- Consulting fees$1,57518%
- Travel & lodging$861%
- Food & beverage$4,29450%
- Education$4826%
- Other$2,19625%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 60 | $2,844 |
| Johnson & Johnson(2 entities) | 11 | $2,110 |
| Gilead(2 entities) | 10 | $410 |
| Merck | 5 | $237 |
| Amgen | 7 | $237 |
| Pfizer | 13 | $206 |
| Genentech USA, Inc. | 10 | $196 |
| Bristol Myers Squibb | 9 | $195 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $183 |
| Daiichi Sankyo Inc. | 4 | $180 |
| Astellas Pharma US Inc | 8 | $161 |
| Coherus Oncology, Inc. | 4 | $158 |
| Janssen Scientific Affairs, LLC | 1 | $148 |
| Sanofi | 6 | $141 |
| Foundation Medicine, Inc. | 1 | $131 |
| GSK | 6 | $120 |
| E.r. Squibb & Sons, L.L.C. | 6 | $109 |
| Array Biopharma Inc | 6 | $101 |
| AstraZeneca | 4 | $73 |
| Incyte Corporation | 1 | $65 |
| AbbVie | 2 | $59 |
| EMD Serono, Inc. | 2 | $54 |
| Taiho Oncology, Inc. | 2 | $51 |
| Morphosys, US Inc. | 3 | $50 |
| Genmab U.S., Inc. | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Seagen Inc. | 2 | $39 |
| Pharmaessentia USA Corporation | 2 | $36 |
| Tersera Therapeutics LLC | 2 | $35 |
| Rigel Pharmaceuticals, Inc. | 2 | $34 |
| Tesaro, Inc. | 1 | $28 |
| Bayer | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Mirati Therapeutics, Inc. | 1 | $23 |
| Exelixis Inc. | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $21 |
| Tempus AI, Inc | 1 | $17 |
| AVEO Pharmaceuticals, Inc. | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARVYKTI$1,700
- DARZALEX$1,575
- TECVAYLI$1,575
- Yescarta$223
- Erleada$148
- AKEEGA$148
- Pipeline$148
- KEYTRUDA$147
- FOUNDATIONONE$131
- FOUNDATIONONE HEME$131
- FOUNDATIONONE CDX$131
- FOUNDATIONFOCUS$131
- FOUNDATIONONE LIQUID$131
- RYBREVANT$125
- Enhertu$124
- AIMOVIG$122
How this compares
$8,633 in reported general payments places this provider in the 80th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 111 | $1,879,223 |
| CalquenceAcalabrutinib Maleate | 87 | $1,241,493 |
| Lenalidomide | 39 | $501,330 |
| BrukinsaZanubrutinib | 32 | $455,112 |
| LynparzaOlaparib | 23 | $421,417 |
| KisqaliRibociclib Succinate | 30 | $406,421 |
| NubeqaDarolutamide | 24 | $298,344 |
| ImbruvicaIbrutinib | 17 | $249,901 |
| JaypircaPirtobrutinib | 12 | $239,989 |
| PromactaEltrombopag Olamine | 12 | $159,573 |
| LonsurfTrifluridine/Tipiracil Hcl | 13 | $153,971 |
| SprycelDasatinib | 12 | $140,346 |
| EliquisApixaban | 59 | $56,609 |
| ProcritEpoetin Alfa | 13 | $50,195 |
| Abiraterone Acetate | 26 | $47,230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $195 | $1,879,223111 claims |
| AstraZenecaCalquence, Lynparza | $73 | $1,662,911110 claims |
| NovartisKisqali, Promacta | $2,844 | $565,99342 claims |
| BayerNubeqa | $25 | $298,34424 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $183 | $249,90117 claims |
| Taiho Oncology, Inc.Lonsurf | $51 | $153,97113 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $109 | $140,34612 claims |
| PfizerEliquis | $206 | $56,60959 claims |
| Johnson & JohnsonProcrit | $2,110 | $50,19513 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $148 | $47,23026 claims |
| AbbVieVenclexta | $59 | $42,47911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Royal Oak
- Samer BallouzRoyal Oak$29K
- Matthew CotantRoyal Oak$17K
- Elisa QuirozRoyal Oak$13K
- Laura NadeauRoyal Oak$11K
- Martin TapiaRoyal Oak$10K
- Deepa JagtapRoyal Oak$9K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.